Article Information
History
- June 12, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Pyry Helkkula, MEng1,
- Tuomo Kiiskinen, MD1,2,
- Aki S. Havulinna, DSc (Tech)1,2,
- Juha Karjalainen, PhD1,3,4,
- Seppo Koskinen, MD, PhD2,
- Veikko Salomaa, MD, PhD2,
- FinnGen,
- Mark J. Daly, PhD1,3,4,
- Aarno Palotie, MD, PhD1,4,5,
- Ida Surakka, PhD1,6 and
- Samuli Ripatti, PhD1,4,7,†
- 1Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
- 2Finnish Institute for Health and Welfare, Helsinki, Finland
- 3Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- 4Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA
- 5Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry, Analytic and Translational Genetics Unit, Department of Medicine, and the Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
- 6Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
- 7Department of Public Health, University of Helsinki, Helsinki, Finland
- ↵†Corresponding author: Samuli Ripatti, PhD, Institute for Molecular Medicine Finland, HiLIFE, PO Box 20, FI-00014 University of Helsinki, Finland and Broad Institute of MIT and Harvard, Cambridge, MA, +358 40 567 0826, samuli.ripatti{at}helsinki.fi
Posted June 12, 2020.
ANGPTL8 protein-truncating variant and the risk of coronary disease, type 2 diabetes and adverse effects
